JP2007530580A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530580A5
JP2007530580A5 JP2007505191A JP2007505191A JP2007530580A5 JP 2007530580 A5 JP2007530580 A5 JP 2007530580A5 JP 2007505191 A JP2007505191 A JP 2007505191A JP 2007505191 A JP2007505191 A JP 2007505191A JP 2007530580 A5 JP2007530580 A5 JP 2007530580A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
medicament
inflammatory
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007505191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530580A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009899 external-priority patent/WO2005097780A1/en
Publication of JP2007530580A publication Critical patent/JP2007530580A/ja
Publication of JP2007530580A5 publication Critical patent/JP2007530580A5/ja
Abandoned legal-status Critical Current

Links

JP2007505191A 2004-03-26 2005-03-24 肥満細胞トリプターゼインヒビターとしての［４−（５−アミノメチル−２−フルオロ−フェニル）−ピペリジン−１−イル］−（４−ブロモ−３−メチル−５−プロポキシ−チオフェン−２−イル）−メタノンヒドロクロリド Abandoned JP2007530580A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26
PCT/US2005/009899 WO2005097780A1 (en) 2004-03-26 2005-03-24 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Publications (2)

Publication Number Publication Date
JP2007530580A JP2007530580A (ja) 2007-11-01
JP2007530580A5 true JP2007530580A5 (enExample) 2008-05-08

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505191A Abandoned JP2007530580A (ja) 2004-03-26 2005-03-24 肥満細胞トリプターゼインヒビターとしての［４−（５−アミノメチル−２−フルオロ−フェニル）−ピペリジン−１−イル］−（４−ブロモ−３−メチル−５−プロポキシ−チオフェン−２−イル）−メタノンヒドロクロリド

Country Status (25)

Country Link
US (1) US20070142435A1 (enExample)
EP (1) EP1737848A1 (enExample)
JP (1) JP2007530580A (enExample)
KR (1) KR20060130682A (enExample)
CN (1) CN1956978A (enExample)
AR (1) AR048336A1 (enExample)
AU (1) AU2005230934A1 (enExample)
BR (1) BRPI0509245A (enExample)
CA (1) CA2560649A1 (enExample)
CR (1) CR8603A (enExample)
DO (1) DOP2005000039A (enExample)
EC (1) ECSP066878A (enExample)
IL (1) IL178031A0 (enExample)
MA (1) MA28547B1 (enExample)
MX (1) MXPA06010610A (enExample)
NO (1) NO20064811L (enExample)
PA (1) PA8627601A1 (enExample)
PE (1) PE20060084A1 (enExample)
RU (1) RU2330034C1 (enExample)
TN (1) TNSN06278A1 (enExample)
TW (1) TW200602035A (enExample)
UA (1) UA83738C2 (enExample)
UY (1) UY28821A1 (enExample)
WO (1) WO2005097780A1 (enExample)
ZA (1) ZA200607752B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
AR065858A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
WO2008121669A1 (en) * 2007-03-29 2008-10-09 Sanofi-Aventis 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
ES2469824T3 (es) 2007-11-21 2014-06-20 Janssen Pharmaceutica N.V. Espiropiperidinas para su uso como inhibidores de la triptasa
WO2009094641A2 (en) * 2008-01-24 2009-07-30 Dor Biopharma, Inc. Topically active steroids for use in interstitial pulmonary fibrosis
WO2010022196A2 (en) * 2008-08-22 2010-02-25 Sanofi-Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
CN102574792B (zh) 2009-09-24 2014-07-09 赛诺菲-安万特美国有限责任公司 (4-氟-3-(哌啶-4-基)-苯甲基)-氨基甲酸叔丁酯的合成及其中间体
AU2010333779A1 (en) * 2009-12-23 2012-07-12 Sanofi Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors
JP2013515724A (ja) * 2009-12-23 2013-05-09 サノフイ ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類
EP2515851A1 (en) * 2009-12-23 2012-10-31 Sanofi Treatment for inflammatory bowel disease
BR112012020965A2 (pt) * 2010-02-24 2016-05-03 Sanofi Sa tratamento de condições alérgicas dermatológicas
MX360706B (es) 2011-10-07 2018-11-14 Takeda Pharmaceuticals Co Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.
UA126574C2 (uk) * 2017-02-10 2022-11-02 Дженентек, Інк. Антитіло проти триптази, його композиція та застосування

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
IL152830A0 (en) * 2000-05-22 2003-06-24 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors

Similar Documents

Publication Publication Date Title
JP2007530580A5 (enExample)
JP5567252B2 (ja) グリコピロレートおよびベータ２アドレナリン受容体アゴニストの組合せ剤
RU2006137717A (ru) [4-(-аминометил-2-фторфенил)-пеперидин-1-ил]-(4-бром-3-метид-5-пропокситиофен-2-ил)-метанон гидрохлорид как ингибитор триптазы тучных клеток
US20100166671A1 (en) Organic compounds
JP2010215637A (ja) β２−アゴニストの溶液を含有する加圧式定量用量吸入器
CA2496699A1 (en) Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
JP2009535340A5 (enExample)
RU2008129600A (ru) Комбинация и фармацевтический препарат для лечения воспалительных заболеваний
CN1341017A (zh) 用于治疗气喘的福莫特罗和糖酸莫米松的组合
AU2012216890A1 (en) Combination of glycopyrrolate and a beta2 -agonist
JP2017526716A5 (enExample)
JP2019528316A5 (enExample)
CN101657191B (zh) 包括福莫特罗和二丙酸倍氯米松的组合物在制备用于预防和/或治疗哮喘恶化的药物中的用途
CA2575932A1 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
JP2022520990A (ja) 呼吸器疾患の治療の方法
KR20080068085A (ko) 삼중-조합 요법을 이용한 천식 및 ｃｏｐｄ의 치료
ES2319887T3 (es) Formulacion superfina de salmeterol.
CN106470700A (zh) 用于治疗copd的噻托溴铵、福莫特罗和布地奈德的组合
CN101312721A (zh) 包含格隆铵盐的有机化合物
KR20080069197A (ko) 염증성 및 폐쇄성 기도 질환의 치료를 위한 제약 조성물
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
JP2010538010A5 (enExample)
JP2016506947A (ja) 吸入療法において使用するのに適する多成分結晶粒子を含む医薬組成物
JP2006501207A5 (enExample)
JP2008533079A5 (enExample)